Question:
1. What is the test menu and testing volumes from each site?

2. What is the QC testing protocol from each site?

3. Is the proposal to install 42 instruments to replace the existing systems 1:1 – will additional or backup systems be required?

Answered on 15/Oct/2025 01:34 PM:


1. Test volumes will be provided as an addendum.

2. QC testing protocols are variable at each site and based on the number of tests per site. The general rule is that for 24/7 labs, routine testing is done QC per 8-hour shift. For low testing numbers, it would be once per day.

3. The plan is to assess what the supplier offers and we may see less need for instruments, or we may decide to purchase more. Some sites with an analyser life period and an increase in workload may look to increase their automation and offer redundancy.

Question:
Is it possible to extend the closing date for this tender?

Answered on 15/Oct/2025 01:20 PM:


Unfortunately, we are unable to grant any extensions at this time. The current timeline has been carefully structured to ensure we meet critical project milestones, and any delays would significantly impact downstream activities.

Question:
1. We would like to request an extension to the closing date for submissions.

2. Total Laboratory Automation (TLA):

Are any QH laboratories currently utilizing a TLA track system for coagulation analysers?

Are there plans to implement TLA track systems in any QH laboratories in the future and to have coagulation analysers attached to the track systems? If so, please could you indicate which laboratories.

3. Consumables Definition: Does the term "consumables" in your documentation refer to both reagents and consumables?

4. What individual assays are included in the ‘Thrombophilia Panel’?

5. What individual assays are included in the COAG Panel?

8. What individual assays are included in the FIBC Panel?

9. What individual assays are included in the vW Panel?

Answered on 21/Oct/2025 05:06 PM:


1:

Question: We would like to request an extension to the closing date for submissions.

Answer: Unfortunately, we are unable to grant any extensions at this time. The current timeline has been carefully structured to ensure we meet critical project milestones, and any delays would significantly impact downstream activities.

2.

Question: Total Laboratory Automation (TLA): Are any QH laboratories currently utilizing a TLA track system for coagulation analysers? Are there plans to implement TLA track systems in any QH laboratories in the future and to have coagulation analysers attached to the track systems? If so, please could you indicate which laboratories.

Answer: Currently, there are no coagulation analysers on tracks, and at this time, there are no plans to place coagulation analysers onto tracked systems. However, should plans change in the future, the laboratories with existing tracked systems in Chemical Pathology are Gold Coast, Princess Alexandra Hospital, (RBWH) and Townsville.

3.

Question: Consumables Definition: Does the term "consumables" in your documentation refer to both reagents and consumables?

Answer: Yes, the definition of consumables here includes reagents.

4.

Question: What individual assays are included in the ‘Thrombophilia Panel’?

Answer: Activated Protein C Resistance, Protein C, Protein S, Antithrombin and LUPUS Screen

5.

Question: What individual assays are included in the COAG Panel?

Answer: PT / INR / APTT / Fibrinogen (Some sites are Derived and others are Clottable), Clottable sites with FibC as part of COAH panel include QCH, RBWH and GCUH.

6.

Question: What individual assays are included in the FIBC Panel?

Answer: This is not a panel. It is Fibrinogen Clottable only.

7.

Question: What individual assays are included in the vW Panel?

Answer: Factor VIII one-stage clot based, vW antigen, vW GP1bR activity and Collagen Binding

Question:
1. D-Dimer Testing: Please provide the number of D-Dimer tests performed per laboratory. These were not included in the assay list in Addendum 1.

2. Protein C Assay Method: Could you confirm whether the Protein C assay is performed using the clotting method or the chromogenic method? Additionally, please provide the test volumes for each method.

3. Protein S Testing: Please provide the number of tests performed for both Protein S Free and Protein S Total.

4. Echis Testing: Is Echis testing conducted at all laboratory sites? Also, is this assay used for Direct Thrombin Inhibitor testing (e.g., Dabigatran)?

5. Maryborough Laboratory: On page 25 of Part B of SOA, there are no analyser requirements listed for Maryborough Lab, although test volumes are provided. Can you confirm whether Maryborough requires an analyser(s)? If not, should the test volumes listed for this site be disregarded?

6. LUPUS testing - what percentage (or numbers per year) of Lupus Screen do you confirm?

Answered on 17/Oct/2025 02:17 PM:


1.

Question: D-Dimer Testing: Please provide the number of D-Dimer tests performed per laboratory. These were not included in the assay list in the Addendum.

Answer: D-Dimer test numbers have been provided in Addendum 2.

2.

Question: Protein C Assay Method: Could you confirm whether the Protein C assay is performed using the clotting method or the chromogenic method? Additionally, please provide the test volumes for each method.

Answer: The Protein C assay is performed using the Chromogenic method, and test volumes have been provided in Addendum 1.

3.

Question: Protein S Testing: Please provide the number of tests performed for both Protein S Free and Protein S Total.

Answer: Only Protein S Free is tested. Immunoturbidimetric assay. The number of tests performed for Protein S Free has been provided in Addendum 1.

4.

Question: Echis Testing: Is Echis testing conducted at all laboratory sites? Also, is this assay used for Direct Thrombin Inhibitor testing (e.g., Dabigatran)?

Answer: Echis is tested in most tertiary level laboratories only. It is an in-house assay used for liver dysfunction and vitamin K deficiency. It is included to show the workload of tests. It is not a DTI assay.

5.

Question: Maryborough Laboratory: On page 25 of Part B of SOA, there are no analyser requirements listed for Maryborough Lab, although test volumes are provided. Can you confirm whether Maryborough requires an analyser(s)? If not, should the test volumes listed for this site be disregarded?

Answer: Maryborough laboratory refers samples to Hervey Bay for testing, so Maryborough test numbers should be counted towards Harvey Bay.

6.

Question: LUPUS testing - what percentage (or numbers per year) of Lupus Screen do you confirm?

Answer: Approximately 20%

Question:
Can D-dimer test numbers for each site please be provided?

Answered on 17/Oct/2025 01:59 PM:


Yes, D-dimer test numbers have now been provided. Please see Addendum 2.

Question:
Can you please list what tests are included in a thrombophilia panel?

Can you please confirm that the test numbers provided in document VP482429_Addendum_CSD127341 - Addendum 1 are annual test numbers per site. These numbers appear to be very low for annual test volume.

Answered on 21/Oct/2025 05:14 PM:


1.

Question: Can you please list what tests are included in a thrombophilia panel?

Answer: Activated Protein C Resistance, Protein C, Protein S, Antithrombin and LUPUS Screen.

2.

Question: Can you please confirm that the test numbers provided in document VP482429_Addendum_CSD127341 - Addendum 1 are annual test numbers per site.

Answer: Yes, the test numbers provided are annual figures.

Question:
1. No Reptilase numbers have been provided, please could these be made available by laboratory


2. "Part B Standing Offer Arrangement (SOA) Details Medical Equipment", Section 3 Requirements clearly states the assays required to be performed on Small, Medium and Large analysers and, by association, at which sites those assays are to be performed.

For example:

Small analysers - PT, APTT, Fibrinogen, Echis, TCT, D Dimer and Anti Xa.

Medium analysers - PT, APTT, Fibrinogen, Echis, TCT, D Dimer, Anti Xa, Intrinsic Factors and ATIII.

Large analysers - PT, APTT, Fibrinogen, Echis, TCT, D Dimer, Anti Xa, Intrinsic Factors, Extrinsic Factors, ATIII, vWF screening, Lupus, and Thrombophilia screens.

However, the test numbers provided show many of the Small analyser sites are currently testing Factors (both Intrinsic and Extrinsic), Protein C and S, ATIII, vWF and Lupus screens.

Likewise for the Medium analyser sites.

It seems unrealistic for many of the Small sites to be running such small volume of testings eg. 1-2 Factor V per annum, 1-3 Protein S per annum.

Do you plan to consolidate testing of the non-described assays to the larger sites or do we continue to plan for the Small and Medium sites to be performing these very low number assays which only increases Reagent, Cal and QC usage and costs?

Answered on 24/Oct/2025 03:17 PM:


1.

Question: Could you please provide the Reptilase test volumes and the laboratories that perform this test?

Answer: Approximately 150 tests annually, conducted exclusively at PAH and QCH.

2.

Question: Do you plan to consolidate testing of the non-described assays at the larger sites, or do we continue to plan for the Small and Medium sites to perform these very low-number assays?

Answer: A new addendum (Number 3) has been added to indicate if tests are performed locally or in a group laboratory.

Question:
Can we please confirm that the test numbers provided in document VP482429_Addendum_CSD127341 - Addendum 1 for annual testing volumes indicate average daily test counts at RBWH as the following for these tests (total number provided/365):

Request Code Daily averages RBWH

Anti-10a 6

APIX 0

APTT 16

APTT (mix) 2

AT3 1

COAG 91

Echis 2

F10 0

F11 0

F2 0

F5 0

F7 0

F8 1

F9 1

FIBC 10

HIT 0

INR 13

Lupus 5

Prot C 1

Prot S 1

PT 13

PT (mix) 0

RIVAR 0

TCT 0

THROMB 1

VW panel 1

D-Dimer 7

Answered on 24/Oct/2025 12:38 PM:


The testing volumes provided reflect average daily test counts at RBWH. For tests exclusively performed at RBWH (e.g. THROMB), the total annual volume represents the statewide workload. To estimate the daily workload, divide the total by 365.

Question:
1. Echis testing: As it’s a lab developed assay, could you please share the current method for Echis test so we can accurately calculate your needs with our products?

2. Please provide Reptilase test numbers and which labs run Reptilase.

3. EMR Connectivity:

Could you please clarify the purpose of the questions regarding connection to the Oracle Health EMR in Part C Tab 8. Oracle Health?

Are you able to provide connectivity diagrams to help us better understand the integration requirements?

Eg. What is the structure of Oracle EMR, LIS and other middleware within QH? What does the CA connect to?

4. LIS and Oracle Integration:

How does the LIS data manager interface with Oracle? Any details on the architecture or data flow would be appreciated.

Answered on 29/Oct/2025 12:49 AM:


1.

Question: Echis testing: As it’s a lab developed assay, could you please share the current method for Echis test so we can accurately calculate your needs with our products?

Answer:

The Echis test is a modified prothrombin time (PT) assay utilising an in-house developed reagent.

2.

Question: Please provide Reptilase test numbers and which labs run Reptilase.

Answer:

Approximately 150 tests are conducted annually, exclusively at PAH and QCH.


3.

Question: Could you please clarify the purpose of the questions regarding connection to the Oracle Health EMR in Part C Tab 8. Oracle Health?

Answer:

Please disregard Tab 8. Oracle Health. Please see Addendum 4 and complete the replacement of Tab 8 'Addendum 4 - Tab 8. LIS - ITO Part C Response - Schedule of Particulars - Coagulation Analysers'.

4.

Question:

LIS and Oracle Integration: How does the LIS data manager interface with Oracle? Any details on the architecture or data flow would be appreciated.

Answer:

The Analysers must be able to integrate into a Laboratory Information System using either HL7v2.x or ASTM E1394 protocol. All proposed solutions must support Bi-Directional communication for exchanging patient demographics, test orders and results at a minimum.

The LIS is integrated bidirectionally to the Oracle Health System and receives HL7 patient order information via Rhapsody Integration Engine. Orders are consumed by the LIS and records are created internally to the LIS. Results are processed by the LIS and then finally sent back to the Oracle Health System via the same bidirectional HL7 interface, utilising Rhapsody Integration Engine.

Additionally, we do not require the devices to be integrated directly with Oracle Health EMR, but we are interested in seeing the integration solutions you have for LIS’s that are connected to an EMR - as this can affect the bidirectional integration solution they develop.

Question:
Can you please advise for Anti-Xa testing, what is the split of UFH and LMWH?

Answered on 24/Oct/2025 12:31 PM:


We do not differentiate between Clex and UFH. We report both as an Anti-Xa level on the same test code. Anti-Xa code includes both Clex and UFH.

Question:
Can you please provide a list of tests that are exclusively run at RBWH?

Answered on 28/Oct/2025 04:54 PM:


Question: Can you please provide a list of tests that are exclusively run at RBWH?

Answer:

1- Lupus Testing:

- Performed at RBWH.

- Exception: PAH performs its own testing.

2- Factor XI (F11) and Factor XII (F12) Testing:

- Performed at RBWH.

- Exception: QCH performs its own testing.

3- VW Testing:

- Performed at RBWH.

- Exceptions: GCUH and QCH perform their own testing.

Question:
Regarding Tab 11. Client Workstation in Part C Response.

Is this tab referring to the PC associated with the analyser or is this with regards to a PC to connect to the middleware solution?

Answered on 28/Oct/2025 09:48 PM:


Question: Regarding Tab 11. Client Workstation in Part C Response. Is this tab referring to the PC associated with the analyser or is this with regards to a PC to connect to the middleware solution?

Answer: Tab 11 refers to the client workstation that is associated with the analyser, not a separate PC.

Question:
Regarding the requirement in CSD127341_ITO_Part_C_Response-Schedule_of_Particulars-Coagulation_Analyser can you please explain some specific scenarios, examples or workflows that make this a mandatory requirement?


(e) changing the sample status once loaded on the analyser?

(g) adding on tests whilst running?

Thanks.

Answered on 29/Oct/2025 02:31 PM:


(e) Changing the sample status once loaded on the analyser: If an analyser is operating at full capacity, changing the sample status to urgent while it is already in-flight allows the system to prioritise critical samples for faster processing.

(g) Adding on tests whilst running: For example, during a COAG panel, if a prolonged APTT, the laboratory may need to add on further investigative tests such as heparin assays or mixing studies in real time.

Question:
Can Queensland health please confirm that the INR and PT test columns refer to separate tests or is the INR column just referring to an INR result calculated from a PT test? The numbers quoted are very similar and, in some cases, identical

What is part of the Lupus Screen?

Answered on 31/Oct/2025 02:41 PM:


1.

Question: Can Queensland Health please confirm that the INR and PT test columns refer to separate tests or is the INR column just referring to an INR result calculated from a PT test?

Answer: Yes, INR and PT are the same test.

2.

Question: What is part of the Lupus Screen?

Answer: DRVVT and APTT pathways with phospholipid sensitive and insensitive reagents. Including mixes with normal pool.

Question:
More questions to ask please



1. Does each laboratory place orders to the Suppliers individually or does a consolidated Reagent and Consumable order come from a central location?

2. Are Suppliers expected to deliver reagents and consumables to each individual laboratory location or are deliveries made to a central metro location and QH distribute the reagents and consumables to the laboratories using their own internal distribution network?

3. Can you confirm what 'OQI' means or refers to as in NCR/OQI in Part B SOA Details Coagulation Analysers p 47, Service Maintenance Item 5?

Thank you

Answered on 31/Oct/2025 02:50 PM:


1.

Question: Does each laboratory place orders to the Suppliers individually or does a consolidated Reagent and Consumable order come from a central location?

Answer: Each laboratory places its own orders directly with the suppliers.

2.

Question: Are Suppliers expected to deliver reagents and consumables to each individual laboratory location or are deliveries made to a central metro location and QH distribute the reagents and consumables to the laboratories using their own internal distribution network?

Answer: Suppliers are expected to deliver reagents and consumables directly to each individual laboratory location.

3.

Question: Can you confirm what 'OQI' means or refers to as in NCR/OQI in Part B SOA Details Coagulation Analysers p 47, Service Maintenance Item 5?

Answer: OQI refers to Operational Quality Issue and NCR is Non-Conformance Report.